Terazosin: Ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension

American Journal of Hypertension

Volumn 9, Issue 5, 1996, Pages 437-444

  Hernández, Rafael Hernández ^a   Angeli Greaves, Miriam ^a   Carvajal, Atiff Rafael ^a   Pajuelo, Jaime Guerrero ^a   Padilla, María Cristina Armas ^a   Armas Hernández, María José ^a  

^a UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

Author keywords

Doxazosin; Hypertension; Plasma lipids; Platelet aggregation; Terazosin; 1 Adrenergic blockers

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; COLLAGEN; DOXAZOSIN; ENDOGENOUS COMPOUND; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TERAZOSIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

EID: 17344388097     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-7061(95)00436-X     Document Type: Article

References (37)

1. Kannel WB, Wolf PA, Verter J, McNamara PM: Epidemiological assessment of the role of blood pressure in stroke: the Framingham study. JAMA 1970;214:301-310.
2. Castelli WP: Epidemiology of CHD: the Framingham study. Am J Med 1984;76:4-12.
3. Stamler J, Wentworth D, Neaton JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356.222 primary screen of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256:2823-2828.
4. Ferrannini E, Buzzigoli G, Bonadonna R, et al: Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-357.
5. Haft J: Role of blood platelets in coronary artery disease. Am J Cardiol 1979;43:1197.
6. Weiss H: Platelets and ischemic heart disease. N Engl J Med 1980;301:225-226.
7. Packham M: Methods for detection of hypersensitive platelets. Thromb Haemost 1978;40:175-195.
8. Hernández R, Carvajal AR, Guerrero-Pajuelo J, et al: The effect of doxazosin on platelet aggregation in normotensive subjects and essential hypertensive patients: an in vitro study. Am Heart J 1991;121:389-394.
9. Kannel WB, Scharzkin A: Risk factor analysis. Prog Cardiovasc Dis 1983;26:309-332.
10. Houston MC: New insights and new approaches for the treatment of essential hypertension: selection of therapy based on coronary heart disease risk factor analysis, haemodynamic profiles, quality of life, and subsets of hypertension. Am Heart J 1989;117:911-951.
11. Graham RM, Pettinger WA: Prazosin. New Engl J Med 1979;5:232-236.
12. Hernández R, Armas de Hernández MJ, Armas-Padilla MC, et al: Doxazosin in the treatment of arterial hypertension: its effects of exercise and spirometry. Curr Ther Res 1988;43:610-620.
13. Dauer AD: Terazosin: an effective once-daily monotherapy for the treatment of hypertension. Am J Med 1986;80(suppl 5B):29-34.
14. Grimm RH: Antihypertensive therapy: taking lipids into consideration. A Heart J 1991;122:910-918.
15. Elliott HL, Meredith PA, Sumner DJ, et al: A pharmacodynamic and pharmacokinetic assessment of a new alpha-1-adrenoceptor antagonist, doxazosin (UK, 33.274) in normotensive subjects. Br J Clin Pharmacol 1982;13:699.
16. Elliot HL, Meredith PA, Reid JL: Pharmacokinetic overview of doxazosin. Am J Cardiol 1987;57:78G.
17. Ikeda T, Nonaka Y, Goto A, Ishii M: Effects of prazosin on platelet aggregation and plasma beta-thromboglobulin in essential hypertension. Clin Pharmacol Ther 1985;37:601.
18. Hernández R, Guerrero-Pajuelo J, Carvajal AR, et al: Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension: an ex-vivo study. Am Heart J 1991;121:395-401.
19. Patterson SE: Terazosin kinetics after oral and intravenous doses. Clin Pharmacol Ther 1985;38(4):423-427.
20. Sonders RC: Pharmacokinetics of terazosin. Am J Med 1986;80(suppl 5B):20-24.
21. Kondo, Ohashi K, Ebihara A: The pharmacokinetics and pharmacological effects of terazosin. A new a blocking agent in normotensive volunteers. Jpn J Clin Pharmacol Ther 1983;14:147.
22. Born GVR: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927.
23. Kyncl JJ: Pharmacology of terazosin. Am J Med 1986;80(suppl 5B):12-19.
24. Frishman WH, Eisen G, Lapsker J: Terazosin: A new long-acting alpha-1-adrenergic antagonist for hypertension. Med Clin North Am 1988;72(2):441-447.
25. Hernández R, Carvajal AR, Armas-Hernández MJ, et al: Amlodipine in hypertension: its effects on platelet aggregation and dynamic exercise. J Cardiovasc Pharmacol 1991;17(suppl 1):S25-S27.
26. Hernández R, Armas-Hernández MJ, Carvajal AR, et al: Amlodipine and cilazapril on platelet aggregation in patients with hypertension (abst). Am J Hypertens 1994;4(part 2):37A.
27. The Steering Committee of the Physicians Health Study Research Preliminary Report: Finding from the aspirin component of ongoing physicians health study. New Engl J Med 1988;18:262-264.
28. Gent M, Blakely JA, Easton JD: The Canadian-American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;i:1215-1220.
29. The Ducth TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs. 283 mg) in patients after a transient ischemic attack or minor ischemic stroke. New Engl J Med 1991;325(18):1261-1266.
30. Deger, G: Effect of terazosin on serum lipids. Am J Med 1986;80(suppl 5B):82-85.
31. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial. Results I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-374.
32. Frick EH, Elo O, Haap AK, et al: The Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dislipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
33. Sacks FM, Dzau VJ: Adrenergic effects on plasma lipoprotein in metabolism. Speculations of mechanisms of actions. Am J Med 1986;80(suppl 2A):71-81.
34. Hauss WH, Bauch HJ, Schulte H: Adrenaline and noradrenaline as possible chemical mediators in the pathogeneissi of arteriosclerosis. Ann N Y Acad Sci 1990; 598:91-101.
35. Exton JH: Mechanisms involved in alpha-adrenergic phenomena: role of calcium ions in actions of catecholamines in liver and other tissues. Am J Physiol 1980;238:E8-E12.
36. Swindell AC, Valentine JJ: Effects of doxazosin on diet-induced hypercholesterolemia in C57BR/ cdj mice. Am J Cardiol 1987;59:29G-34G.
37. The fifth report of the Join National Committee on the Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1993;153:154-183.